Scott Lish Sells 16,666 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Key Points

• Scott Lish, COO of Alphatec Holdings, sold 16,666 shares of the company's stock for approximately $249,990, which decreased his ownership stake by 2.41%.
• Alphatec's stock currently trades at $15.34, reflecting a 3.2% increase and a significant rise from its one-year low of $4.88.
• The company reported a 27.5% increase in revenue year-over-year, achieving $185.54 million for the last quarter, which exceeded analysts' expectations.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 16,666 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $15.00, for a total transaction of $249,990.00. Following the completion of the sale, the chief operating officer owned 674,332 shares of the company's stock, valued at approximately $10,114,980. This trade represents a 2.41% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Scott Lish also recently made the following trade(s):

• On Monday, August 4th, Scott Lish sold 17,857 shares of Alphatec stock. The shares were sold at an average price of $14.00, for a total transaction of $249,998.00.
• On Friday, August 1st, Scott Lish sold 36,081 shares of Alphatec stock. The stock was sold at an average price of $12.53, for a total transaction of $452,094.93.
• On Thursday, July 10th, Scott Lish sold 3,982 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total transaction of $47,784.00.
• On Friday, June 13th, Scott Lish sold 22,727 shares of Alphatec stock. The stock was sold at an average price of $11.07, for a total transaction of $251,587.89.
• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The stock was sold at an average price of $13.00, for a total transaction of $719,875.00.

Alphatec Stock Performance

NASDAQ ATEC traded down $0.30 during midday trading on Thursday, hitting $14.90. The company had a trading volume of 4,026,655 shares, compared to its average volume of 2,076,670. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -13.19 and a beta of 1.05. The firm has a fifty day simple moving average of $11.53 and a two-hundred day simple moving average of $11.23. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $15.46.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.08. The company had revenue of $185.54 million for the quarter, compared to analyst estimates of $178.85 million. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The business's quarterly revenue was up 27.5% on a year-over-year basis. During the same period last year, the business posted ($0.29) EPS. Equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Alphatec in a research note on Monday, April 14th. Barclays restated an "overweight" rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research note on Monday. Piper Sandler restated an "overweight" rating and set a $15.00 price target (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Needham & Company LLC restated a "buy" rating and set a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Friday, August 1st. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $18.50.

Institutional Trading of Alphatec

Several hedge funds and other institutional investors have recently bought and sold shares of ATEC. Nuveen LLC bought a new position in shares of Alphatec during the 1st quarter worth about $135,874,000. Vanguard Group Inc. raised its stake in shares of Alphatec by 0.8% during the first quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company's stock worth $60,990,000 after buying an additional 45,792 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Alphatec by 16.9% during the first quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company's stock worth $59,117,000 after buying an additional 840,974 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Alphatec by 10.8% during the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company's stock worth $35,773,000 after buying an additional 342,656 shares during the last quarter. Finally, Nuveen Asset Management LLC raised its stake in shares of Alphatec by 78.4% during the fourth quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock worth $23,730,000 after buying an additional 1,136,330 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.